Skip to main
VNDA

Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target

Vanda Pharmaceuticals (VNDA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Vanda Pharmaceuticals Inc. is positioned for significant revenue growth due to its diverse product portfolio and the potential of its compounds, particularly tradipitant, which is now linked to the prevention of nausea and vomiting in patients using GLP-1 receptor agonists. The company’s prospects are further enhanced by the expected long-term market exclusivity for milsaperidone, with exclusivity extending to 2044, which supports robust future revenue streams from approved indications. Additionally, positive clinical trial results for tradipitant may lead to increased demand and enhanced compliance for therapies that address critical health issues, reflecting the company's strong foundation for innovation and patient benefits.

Bears say

Vanda Pharmaceuticals faces significant risks that negatively affect its financial outlook, primarily due to slower-than-expected sales traction for key products like Fanapt and Ponvory, along with accelerated generic erosion impacting Fanapt and Hetlioz. Additionally, adverse pricing developments, particularly concerning Medicare reimbursement, and potential regulatory setbacks for late-stage pipeline candidates pose further threats to revenue stability. The company also grapples with medium- to long-term dilution risks and uncertainty surrounding operational changes, including potential M&A activities that could destabilize its shareholder base.

Vanda Pharmaceuticals (VNDA) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vanda Pharmaceuticals (VNDA) Forecast

Analysts have given Vanda Pharmaceuticals (VNDA) a Buy based on their latest research and market trends.

According to 5 analysts, Vanda Pharmaceuticals (VNDA) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vanda Pharmaceuticals (VNDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.